kaiser semaglutide criteria Population‐level impact of 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial - Nanna - 2025 - Diabetes, Obesity and Metabolism kaiser semaglutide criteria Semaglutide and

Genetics : Factors like body mass and build can affect how the drug is distributed throughout the body

At the maximum maintenance dose of 2.4mg per week, that same vial drops to roughly 4 doses

Patients who taper off successfully often retain their results with ongoing guidance and support

It estimates the population level treatment effect of semaglutide regardless of treatment adherence and/or other anti-obesity therapies and does not exclude data collected after discontinuation of treatment (e.g., due to tolerability issues) or after initiation of alternative treatment (e.g., due to lack of efficacy)

If you stop, the condition it was managing tends to return

Longer-term studies show even greater weight reduction over several months